Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.3052W HIGH $1.51
Volume
85.46 K
Value Traded
27.52 K
Short % Float
0.7%
Days to Cover
1.2
+5.54%Week
+10.13%1 Month
-26.54%3 Month
-50.48%6 Month
-96.06%5 Year
-99.64%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
4.32 M
EPS (TTM)
-1.50
P/E Ratio
-
Ent. Value
-13.52 M
Total Shares
10.74 M
Float Shares
10.07 M
Insiders
6.21%
Institutions
7.29%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
PMCB Catalyst Timeline
Dated clinical, regulatory and corporate events for PharmaCyte Biotech, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for PharmaCyte Biotech, Inc.
44Total events
0Upcoming
11Tier-1 (high impact)
2013 to 2025Coverage
Event history 35
▼Equity OfferingCorporate
$7 million capital raise via Series C convertible preferred stock and warrants
▼Equity OfferingCorporate
Completed $35 million private placement of convertible redeemable preferred stock and warrants
▼Clinical Hold PlacedCell-in-a-BoxIND
FDA clinical hold placed on IND for Cell-in-a-Box technology
cancer, diabetes, malignant ascitessource ↗
▼Restructuring LayoffsCorporate
Board curtailed spending on programs including pre-clinical and clinical activities pending review
◆Pipeline PrioritizationCorporate
Business Review Committee formed to evaluate strategy and operations
◆Management ChangeCorporate
CEO Kenneth L. Waggoner stepped down; Joshua N. Silverman appointed interim CEO
▲Trial InitiationCypCapsTrial
Commencement of pilot phase of two-phase pig study
locally advanced, inoperable pancreatic cancersource ↗
▲Interim AnalysisCypsCapsTrial
Positive interim results in malignant ascites mouse model study
malignant ascitessource ↗
●Quarterly UpdateCorporate
Preliminary unaudited financial results for fiscal year ended April 30, 2022
▲Preclinical PoCCypCapsPreclinical
Completed study confirming qRT-PCR implementation for pancreatic cancer product candidate
pancreatic cancersource ↗
◆Trial InitiationTrial
Planned Phase 2b clinical trial expected to start in Q3 2022
Pancreatic Cancersource ↗
●Preclinical PoCCypCapsPreclinical
Initiated first in a new series of studies to test pancreatic cancer therapy for malignant ascites
malignant ascitessource ↗
▲Preclinical PoCCypCapsPreclinical
Reported positive results to satisfy FDA requirements related to empty capsule material
pancreatic cancersource ↗
●Trial InitiationCypCapsTrial
Accelerate preparations for start of Phase 2b clinical trial in LAPC
locally advanced, inoperable pancreatic cancer (LAPC)source ↗
▲Preclinical PoCCypCapsPreclinical
Successfully completed 24-month product stability study required by FDA
pancreatic cancersource ↗
▼Clinical Hold PlacedIND
Planned Phase 2b clinical trial placed on clinical hold by FDA
pancreatic cancersource ↗
▼Equity OfferingCorporate
Announced $70 million registered direct offering priced at-the-market
▲Partnership / LicenseCorporate
PharmaCyte enters into License Agreement with Hai Kang for COVID-19 diagnostic kits
COVID-19source ↗
▲Partnership / LicenseCorporate
Restructured agreements with Austrianova to strengthen partnership
▲Partnership / LicenseCorporate
Exclusive worldwide license from Austrianova to combine Cell-in-a-Box with cannabinoids for cancer treatments
cancersource ↗
◆ATM ProgramCorporate
At the Market banking agreement with Chardan Capital Markets for up to $50M
▼Equity OfferingCorporate
Entered into stock purchase agreement with Lincoln Park Capital for up to $27 million
▲Partnership / LicenseCorporate
Acquired exclusive worldwide rights to cellulose-based live-cell encapsulation technology for diabetes
diabetessource ↗
▼Equity OfferingCorporate
Secured $1.5 million funding through sale of restricted stock at $0.15 per share
▲Manufacturing MilestoneCMC / Inspection
Manufacturing agreement signed with Austrianova for cGMP-compliant Cell-in-a-Box encapsulation of cells for clinical trials
advanced, inoperable pancreatic cancersource ↗
Past FDA Catalysts and PDUFA Decisions
How PMCB actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every PMCB program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| CypsCapsTM plus ifosfamide | malignant ascites | 2022-07-19 | overall tumor volume is likely a more accurate way of tracking tumor burden when compared to measuring labeled tumor cell fluorescenceRead More | PharmaCyte Biotech Reports Positive Interim Results in Malignant Ascites Mouse Model StudyRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| WEINSTEIN ROBERTDirector | Grant/Award | 119,170 119,170 held | $0.00 | 03/31/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in PMCB
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in PMCB for Q2 2026. | ||||
Ownership Trends
PMCB Short Interest
Shares sold short, counted twice a month.
0.7%
Short % of Float
of tradable shares sold short
50.7K
Shares Sold Short
-27.7% vs prior count
1.2 Low
Days to Cover
trading days of normal volume to buy every short share back
42.5K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How PMCB ranks across every disease it competes in
Competitive Position is a premium feature
See how PMCB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialPMCB News
PMCB▼ -22.9%today
PharmaCyte Biotech, Inc. Announces Reverse Stock Split
PharmaCyte Biotech, Inc. announced a 1-for-19 reverse stock split approved by its board. This decision was ratified by stockholders during the annual meeting on March 30, 2026. The reverse split will take effect on November 12, 2026, at 4:01 p.m. Eastern Time.
Read more →PMCB▲ +36.9%on this news
PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment
PharmaCyte Biotech announced the successful monetization of its Femasys stake, enhancing its financial position. Following this transaction, the company's cash and marketable securities are projected to reach approximately $20 million. CEO Josh Silverman emphasized the importance of strategic capital deployment for shareholder value.
Read more →PMCBPharmaCyte Biotech, Inc. Increases Stake in TNF Pharmaceuticals Around Recent License for Breakthrough Light Speed Computing Platform for Use in Cryptocurrency Applications
PharmaCyte Biotech, Inc. has announced an increased investment in TNF Pharmaceuticals, contributing an additional $3 million to support TNF's recent licensing agreement with LightSolver. This agreement is aimed at utilizing LightSolver's innovative light-based computing technology to enhance speed and efficiency in compute-sensitive applications, particularly in cryptocurrency mining. PharmaCyte highlights its strong financial position with more than $55 million in assets as it prepares to explore additional growth opportunities. However, the company acknowledges the risks involved with successfully implementing this new technology and strategy.
Read more →PMCB▼ -7.2%on this news
PharmaCyte Biotech, Inc. Announces Closing of $7 Million Financing
PharmaCyte Biotech, Inc. announced the closing of a $7 million financing, enhancing its financial position. As of April 30, 2025, the company reported $15.5 million in cash and over $30 million in securities. The interim CEO expressed optimism about the financing's impact on shareholder value and ongoing initiatives.
Read more →PMCB▲ +12.2%on this news
PharmaCyte Biotech, Inc. Announces $7 Million Capital Raise, Led by Existing Investors
PharmaCyte Biotech, Inc. has announced a $7 million capital raise led by existing investors through the sale of newly designated Series C convertible preferred stock. This private placement, expected to close on August 19, 2025, involves the sale of 7,000 shares convertible into a total of 7,000,000 shares of common stock. The capital raise is viewed as a vote of confidence from investors and aims to strengthen the company's financial position. PharmaCyte plans to use the proceeds to enhance shareholder value and explore strategic alternatives.
Read more →PMCBPharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease
PharmaCyte Biotech announced a $7 million investment in MyMD Pharmaceuticals, aimed at enhancing its strategy to create shareholder value. MyMD is advancing its lead product, MYMD-1, which has shown positive results in a Phase 2 trial for sarcopenia. The investment is expected to foster collaboration and further development of MyMD's innovative therapies.
Read more →PMCBmarks expansion of corporate strategy to utilize significant cash position to create additional shareholder value
PharmaCyte Biotech, Inc. (Nasdaq: PMCB) has announced a $5 million investment in Femasys, Inc. (Nasdaq: FEMY), marking an expansion of its corporate strategy to leverage its substantial cash reserves to increase shareholder value. This investment in Femasys, a company dedicated to women's health solutions, includes the appointment of PharmaCyte's interim CEO, Josh Silverman, to Femasys' Board of Directors. The decision comes as PharmaCyte seeks to identify and invest in opportunities outside its drug development to capitalize on its cash position. Nevertheless, PharmaCyte faces challenges, including pending regulatory reviews and clinical holds.
Read more →PMCBPharmaCyte Biotech Acquires $5 Million Stake in Emerging Women’s Health Innovator Femasys, Inc.
PharmaCyte Biotech has made a $5 million investment in Femasys, a company focused on women's health solutions. This marks PharmaCyte's first investment in external technology, leveraging its cash position of approximately $74.6 million. The interim CEO of PharmaCyte will also join Femasys' Board, aiming to enhance collaboration and shareholder value.
Read more →PMCB▲ +12.8%on this news
PharmaCyte Biotech Announces Cash Tender Offer for up to 7,750,000 Shares at $3.25 Per Share Concurrently, the Company Announces $35 Million Financing of Convertible Preferred Stock at $4.00 per Share
PharmaCyte Biotech has announced a cash tender offer for up to 7,750,000 shares at a price of $3.25 per share, which will expire on June 9, 2023. Concurrently, the company completed a $35 million financing through the sale of convertible redeemable preferred stock and warrants from existing investors. This strategy aims to support the company’s ongoing evaluation of its assets associated with treating pancreatic cancer and enhance shareholder value, despite uncertainties regarding the timeline for evaluation. PharmaCyte emphasized the importance of making informed decisions for shareholders in relation to the tender offer.
Read more →PMCBPharmaCyte Biotech to Implement Second $10-Million Share Repurchase Plan
PharmaCyte Biotech announced the authorization of a second $10 million share repurchase program to enhance shareholder value. The program, which takes effect immediately and will run for two years, will be funded by the company's available cash. CEO Josh Silverman emphasized the importance of delivering value to shareholders while managing expenses prudently. The company continues to evaluate its current programs and explore additional strategic opportunities. However, there is uncertainty regarding the program's execution and ongoing evaluations by the Business Review Committee.
Read more →PMCBPharmaCyte Biotech Board of Directors Announces Business Review Committee to Evaluate Opportunities to Optimize Shareholder Value Topics to Include Continued Analysis of FDA's Clinical Hold on IND for Cell-in-a-Box Las V
PharmaCyte Biotech Board of Directors Announces Business Review Committee to Evaluate Opportunities to Optimize Shareholder Value Topics to Include Continued Analysis of FDA's on IND for Cell-in-a-Box Las Vegas, Nev., October 7, 2022 - (Business Wire) - PharmaCyte Biotech, I
Read more →PMCBPharmaCyte Biotech Reaches Cooperation Agreement with Iroquois Capital; Company Appoints Five New Independent Directors to Reconstituted Board
PharmaCyte Biotech Reaches Cooperation Agreement with Iroquois Capital; Company Appoints Five New Independent Directors to Reconstituted Board LAS VEGAS, NV, August 15, 2022 -- (BUSINESS WIRE) -- PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on dev
Read more →PMCBPharmaCyte Biotech Rebukes Iroquois' Commencement of Consent Solicitation 7% owner Attempting to Take Control of Company Without Paying a Control Premium to Shareholders Circumvents Proper Vetting of Direct
PharmaCyte Biotech Rebukes Iroquois' Commencement of Consent Solicitation LAS VEGAS, NV, July 28, 2022, PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes, and malignant ascites using its signature li
Read more →PMCBPharmaCyte Biotech Commences First Phase of Two-Phase Pig Study
PharmaCyte Biotech Commences First Phase of Two-Phase LAS VEGAS, NV, July 21, 2022--(BUSINESS WIRE)-- PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes, and malignant ascites using its signature live-
Read more →PMCBPharmaCyte Biotech Reports Positive Interim Results in Malignant Ascites Mouse Model Study
Reports Positive Interim Results in Malignant Ascites Mouse Model Study LAS VEGAS, NV, July 19, 2022-(BUSINESS WIRE)-PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes, and malignant ascites using its
Read more →PMCBPharmaCyte Biotech Announces Preliminary Unaudited Financial Results for Fiscal Year 2022
PharmaCyte Biotech Announces Preliminary Unaudited Financial Results for Fiscal Year 2022 LAS VEGAS, NV, July 11, 2022 (BUSINESS WIRE) -- PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes and maligna
Read more →PMCBPharmaCyte Biotech Issues Follow-Up Response to Iroquois Capital's Second Letter on June 9 and Reiterates Commitment to Increasing Shareholder Value
PharmaCyte Biotech Issues Follow-Up Response to Iroquois Capital's Second Letter on June 9 and Reiterates Commitment to Increasing Shareholder Value LAS VEGAS, NV, June 15, 2022, PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte), a biotechnology company focused on developin
Read more →PMCBPharmaCyte Biotech Appoints Dr. Matthias L hr to Board of Directors
Appoints Dr. Matthias L hr to Board of Directors LAS VEGAS, NV, April 5, 2022 (BUSINESS WIRE) -- PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation techno
Read more →PMCBThis document may include statements by PharmaCyte Biotech that constitute "forward - looking statements." Such statements are often characterized by the terms "may," "believes," expects" or "anticipates" and do not refl
This document may include statements by PharmaCyte Biotech that constitute "forward - looking statements." Such statements are often characterized by the terms "may," "believes," expects" or "anticipates" and do not reflect facts. Forward - looking statements involve risks, uncer
Read more →About PharmaCyte Biotech, Inc.
Headquarters3960 HOWARD HUGHES PARKWAY, LAS VEGAS, NV, 89169
BIOPHARMAWATCH ELITE
Trade the next PMCB catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime